Dimensional Fund Advisors LP Has $402,000 Stock Position in Solid Biosciences Inc. (NASDAQ:SLDB)

Dimensional Fund Advisors LP boosted its holdings in shares of Solid Biosciences Inc. (NASDAQ:SLDB) by 8.1% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 70,827 shares of the company’s stock after buying an additional 5,287 shares during the period. Dimensional Fund Advisors LP’s holdings in Solid Biosciences were worth $402,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. RA Capital Management L.P. raised its position in Solid Biosciences by 26.4% during the first quarter. RA Capital Management L.P. now owns 4,330,446 shares of the company’s stock valued at $57,682,000 after buying an additional 904,160 shares during the period. Bain Capital Life Sciences Investors LLC raised its position in Solid Biosciences by 28.9% during the first quarter. Bain Capital Life Sciences Investors LLC now owns 4,034,582 shares of the company’s stock valued at $53,741,000 after buying an additional 904,160 shares during the period. Artal Group S.A. increased its position in Solid Biosciences by 175.0% in the 1st quarter. Artal Group S.A. now owns 2,500,000 shares of the company’s stock worth $33,300,000 after purchasing an additional 1,590,781 shares during the last quarter. Janus Henderson Group PLC acquired a new position in Solid Biosciences in the 1st quarter worth about $23,935,000. Finally, Vanguard Group Inc. increased its position in Solid Biosciences by 283.9% in the 1st quarter. Vanguard Group Inc. now owns 1,244,575 shares of the company’s stock worth $16,578,000 after purchasing an additional 920,404 shares during the last quarter. 81.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SLDB has been the topic of several research reports. JPMorgan Chase & Co. raised Solid Biosciences from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $10.00 to $15.00 in a research report on Monday, July 15th. Barclays dropped their target price on Solid Biosciences from $18.00 to $15.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. Piper Sandler reaffirmed an “overweight” rating and issued a $20.00 target price on shares of Solid Biosciences in a research report on Friday, June 21st. William Blair raised Solid Biosciences to a “strong-buy” rating in a research report on Friday, August 30th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Solid Biosciences in a research report on Wednesday, August 14th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Solid Biosciences has an average rating of “Buy” and a consensus target price of $15.67.

Solid Biosciences Stock Performance

SLDB opened at $6.11 on Tuesday. The company has a market cap of $235.85 million, a PE ratio of -1.85 and a beta of 1.90. The stock has a 50-day moving average of $7.89 and a 200-day moving average of $8.44. Solid Biosciences Inc. has a 52-week low of $1.81 and a 52-week high of $15.05.

Solid Biosciences (NASDAQ:SLDB) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.05. On average, research analysts predict that Solid Biosciences Inc. will post -2.61 earnings per share for the current year.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.